CDKN1A and cancer: ACTL6A has been reported to drive cancer progression by stabilizing the YAP1/TAZ pro-cancer transcriptional regulators [18, 19], and by suppressing expression of the p21Cip1 cyclin-dependent kinase inhibitor [20–23].